Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy

被引:6
|
作者
Kadokura, Makoto [1 ]
Maekawa, Shinya [1 ]
Sueki, Ryota [1 ]
Miura, Mika [1 ]
Komase, Kazuki [1 ]
Shindo, Hiroko [1 ]
Amemiya, Fumitake [1 ]
Uetake, Tomoyoshi [1 ]
Inoue, Taisuke [1 ]
Sakamoto, Minoru [1 ]
Nakagawa, Mina [2 ]
Sakamoto, Naoya [2 ]
Watanabe, Mamoru [2 ]
Enomoto, Nobuyuki [1 ]
机构
[1] Univ Yamanashi, Fac Med, Dept Internal Med 1, Chuo Ku, Yamanashi, Japan
[2] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan
来源
PLOS ONE | 2011年 / 6卷 / 09期
关键词
PEGYLATED-INTERFERON-ALPHA; ACID SUBSTITUTION PATTERN; PROTEIN 5A GENE; HIGH VIRAL LOAD; COMBINATION THERAPY; VIROLOGICAL RESPONSE; AMERICAN PATIENTS; PLUS RIBAVIRIN; CORE PROTEIN; MUTATIONS;
D O I
10.1371/journal.pone.0024514
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background and Aims: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and treatment outcome remains unclear. Methods: The pretreatment complete open reading frame (ORF) sequences of genotype 2b HCV determined by direct sequencing were investigated for correlation with the final outcome in a total of 60 patients. Results: In this study group, 87.5% (14/16) of non-sustained virological response (non-SVR) patients (n = 16) were relapsers. Compared to sustained virological response (SVR) patients (n = 44), non-SVR patients were older and could not achieve prompt viral clearance after the therapy induction. Comparing each viral protein between the two groups, viral sequences were more diverse in SVR patients and that diversity was found primarily in the E1, p7, and NS5A proteins. In searching for specific viral regions associated with the final outcome, several regions in E2, p7, NS2, NS5A, and NS5B were extracted. Among these regions, part of the interferon sensitivity determining region (ISDR) was included. In these regions, amino acid substitutions were associated with the final outcome in an incremental manner, depending upon the number of substitutions. Conclusions: Viral sequences are more diverse in SVR patients than non-SVR patients receiving PEG-IFN/RBV therapy for genotype-2b HCV infection. Through systematic comparison of viral sequences, several specific regions, including part of the ISDR, were extracted as having significant correlation with the final outcome.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Hepatitis C Virus Genotype 1: How Genetic Variability of the Core Protein Affects the Response to Pegylated-Interferon and Ribavirin Therapy
    Alhamlan, F. S.
    Al-Ahdal, M. N.
    Khalaf, N. Z.
    Abdo, A. A.
    Sanai, F. M.
    Al-Ashgar, H. I.
    ElHefnawi, M.
    Zaid, A.
    Al-Qahtani, A. A.
    JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (02) : 224 - 234
  • [42] Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
    Alestig, Erik
    Arnholm, Birgitta
    Eilard, Anders
    Lagging, Martin
    Nilsson, Staffan
    Norkrans, Gunnar
    Wahlberg, Thomas
    Wejstal, Rune
    Westin, Johan
    Lindh, Magnus
    BMC INFECTIOUS DISEASES, 2011, 11
  • [43] AUTOIMMUNE DISORDERS DUE TO DOUBLE ANTIVIRAL THERAPY WITH PEGINTERFERON AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS INFECTION
    Docea, Anca Oana
    Gofita, Eliza
    Calina, Daniela
    Ioan, Zaharie Sorin
    Valcea, Daniel Ionica
    Mitrut, Paul
    FARMACIA, 2016, 64 (04) : 605 - 611
  • [44] Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
    Watanabe, Takao
    Joko, Kouji
    Seike, Hirotaka
    Michitaka, Kojiro
    Horiike, Norio
    Kisaka, Yoshiyasu
    Tanaka, Yoshinori
    Nakanishi, Seiji
    Nakanishi, Kimio
    Nonaka, Takashi
    Yamauchi, Kazuhiko
    Onji, Morikazu
    Ohno, Yoshinori
    Tokumoto, Yoshio
    Hirooka, Masashi
    Abe, Masanori
    Hiasa, Yoichi
    SPRINGERPLUS, 2016, 5
  • [45] Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virological Response Reply
    Buti, Maria
    Esteban, Rafael
    HEPATOLOGY, 2010, 52 (04) : 1520 - 1521
  • [46] Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases
    Akuta, Norio
    Suzuki, Fumitaka
    Arase, Yasuji
    Hirakawa, Miharu
    Kawamura, Yusuke
    Yatsuji, Hiromi
    Sezaki, Hitomi
    Suzuki, Yoshiyuki
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Ikeda, Kenji
    Kumada, Hiromitsu
    INTERVIROLOGY, 2010, 53 (03) : 188 - 192
  • [47] Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naive Egyptian Patients With Chronic Hepatitis C Virus Genotype 4
    Abdallah, Fatma
    Mohamed, Gehad
    Ibrahim, Mohsen
    El Tarabily, Mokhtar
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2018, 355 (05) : 456 - 466
  • [48] Cost Effectiveness of Peginterferon α-2a and Peginterferon α-2b Combination Regimens in Genotype-1 Naive Patients with Chronic Hepatitis C
    Gheorghe, Liana
    Baculea, Simona
    HEPATO-GASTROENTEROLOGY, 2010, 57 (101) : 939 - 944
  • [49] Effectiveness of Extending Treatment Duration in Therapy with Pegylated Interferon and Ribavirin for Genotype 2 Hepatitis C Virus Infection
    Nanba, Shintarou
    Ikeda, Fusao
    Fujioka, Shin-ichi
    Araki, Yasuyuki
    Takaguchi, Kouichi
    Hashimoto, Noriaki
    Seki, Hiroyuki
    Takaki, Akinobu
    Iwasaki, Yoshiaki
    Yamamoto, Kazuhide
    ACTA MEDICA OKAYAMA, 2015, 69 (04) : 237 - 244
  • [50] Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients
    Jurczyk, K.
    Laurans, L.
    Karpinska, E.
    Wawrzynowicz-Syczewska, M.
    Parczewski, M.
    Boron-Kaczmarska, A.
    ADVANCES IN MEDICAL SCIENCES, 2011, 56 (02): : 165 - 171